Improved patient outcomes come from new treatments. New treatments stem from successful clinical trials. Clinical trials build on discoveries made in the lab. And laboratory discoveries? Those rely on a vast array of assays...
ASCO guideline emphasizes the importance of assessment for older cancer patients, and a change in mammogram recommendations reignites screening debates.
The FDA has approved an inhibitor of FLT3 for use across multiple phases of acute myeloid leukemia treatment. The U.S. Food and Drug Administration (FDA) has approved quizartinib (Vanflyta) for the treatment of patients...
Black Men With Melanoma Have Higher Risk of Dying, and CAR T-cell Therapy Provides Hope for Aggressive Lymphoma.
Researchers find increased risk of four types of secondary cancer in patients diagnosed with early-onset colorectal cancer.
Reducing cancer treatment to improve quality of life without lowering effectiveness, and death rates are climbing for certain cancers in Hispanic Americans.
Antibody-drug conjugates link a targeted medication with a toxic drug to deliver a potent payload inside cancer cells.
New treatments aim to lengthen remissions and push back recurrences.
Young women who have had hormone receptor-positive breast cancer can safely suspend endocrine therapy to try to have a child.
Adoptive T-cell therapy shows promise in treating metastatic melanoma.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now